Cradle Genomics
Providing knowledge that helps every pregnancy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
$6.0m | Early VC | ||
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 218 % | 45 % | - | (94 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Cradle Genomics is a pioneering company headquartered in San Diego, specializing in non-invasive prenatal testing (NIPT). The company focuses on providing the most comprehensive fetal genetic analysis and pregnancy health screening solutions during the earliest stages of pregnancy. Cradle Genomics serves expectant parents and healthcare providers, aiming to improve patient care and enable global access to advanced prenatal solutions. The business operates in the healthcare and biotechnology market, leveraging cutting-edge genetic analysis of fetal cells collected in the first trimester without posing any risk to the mother or fetus. Cradle Genomics generates revenue through the sale of its prenatal testing services, targeting a broad market of healthcare institutions and individual clients seeking early and accurate prenatal information.
Keywords: prenatal testing, fetal genetic analysis, pregnancy health, non-invasive, first trimester, patient care, healthcare, biotechnology, genetic analysis, prenatal solutions.